Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tagraxofusp + low-intensity chemotherapy
- Development stage
- Unknown
- Lead developer
- Stemline Therapeutics
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Intrathecal, Oral, Subcutaneous
01
Overview
Tagraxofusp (Elzonris) is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin (DT388). It is being investigated by M.D. Anderson Cancer Center in a Phase Ib/II clinical trial (NCT05032183) in combination with a low-intensity chemotherapy regimen for the treatment of relapsed or refractory CD123-positive acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma. The mechanism of action involves the IL-3 domain binding to the CD123 receptor (IL-3 receptor alpha) on the surface of malignant cells, followed by internalization and the subsequent inhibition of protein synthesis by the diphtheria toxin moiety, leading to apoptosis. The low-intensity chemotherapy backbone typically includes agents such as vincristine, dexamethasone, and cyclophosphamide, designed to provide synergistic anti-tumor effects with reduced toxicity compared to standard intensive induction regimens.
- Brand names
- Elzonris
- Other names
- tagraxofusp-erzstagraxofusp
02
Targets
EEF2 (Eukaryotic elongation factor 2)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on tagraxofusp + low-intensity chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tagraxofusp + low-intensity chemotherapy.